Idera Pharmaceuticals is a clinical stage biotechnology company developing a novel approach to the treatment of autoimmune diseases and certain genetically defined forms of B-cell lymphoma. Learn More
4.7.14Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation
3.28.14Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
Idera is advancing to the clinic in genetically defined forms of B-cell lymphoma: activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) and Waldenström’s macroglobulinemia.
Back to top
“TLR structure” by The cat, used under GNU Free Documentation License / Cropped and colored background from original.
© 2014 Idera Pharmaceuticals